Denosumab Market Report 2025

This report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The denosumab market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.7 billion in 2025 at a compound annual growth rate (CAGR) of 13.1%. The growth in the historic period can be attributed to clinical trials and research advancements, FDA approvals and regulatory milestones, growing awareness of bone health, strategic partnerships and marketing initiatives.

The denosumab market size is expected to see rapid growth in the next few years. It will grow to $5.59 billion in 2029 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to rising incidence of bone metastases, advancements in cancer therapies, osteoporosis prevalence, increased awareness of osteoporosis, regulatory approvals for new indications. Major trends in the forecast period include strategic collaborations and partnerships, integration with digital health solutions, expanded indications and clinical applications, advancements in biosimilar development.

The growing prevalence of osteoporosis is expected to drive the expansion of the denosumab market in the future. Osteoporosis is a condition in which bones become fragile, leading to reduced bone density and an increased risk of fractures. Denosumab treats osteoporosis by inhibiting bone resorption through targeting the RANK ligand. For example, in September 2023, the National Center for Biotechnology Information (NCBI), a US-based government agency, reported that data from the Canadian Longitudinal Study on Aging showed a 12.7% prevalence of physician-diagnosed osteoporosis and a 5.9% rate of DXA-confirmed osteoporosis in females among older adults living in the community. Additionally, a cross-sectional study by Buttros and colleagues found a 24.6% prevalence of osteoporosis in postmenopausal women aged 40 to 75, diagnosed using bone mineral density (BMD) measurements. As a result, the increasing prevalence of osteoporosis is fueling the growth of the denosumab market.

Key players within the denosumab market are intensifying their efforts to introduce innovative solutions, particularly first-line treatments for osteoporosis, to gain a competitive advantage. First-line treatment for osteoporosis denotes the initial therapeutic approach recommended by healthcare practitioners for managing individuals diagnosed with the condition. For instance, in November 2022, Boan Biotech, a China-based biotechnology firm, secured approval from China's National Medical Products Administration (NMPA) for its denosumab biosimilar, Boyoubei, becoming the first Chinese company to develop a denosumab injection. Boyoubei is also slated for introduction into markets beyond China, including Europe and the United States, with a global marketing strategy in place. Positioned as a first-line treatment option for osteoporosis in various treatment guidelines, Boyoubei holds promise in significantly reducing the risk of hip, non-vertebral, and vertebral fractures among affected individuals. Notably, Boyoubei stands out as the world's first biosimilar to Prolia (the originator of denosumab) to receive marketing approval.

In June 2022, Organon, a pharmaceutical company headquartered in the United States, entered into a partnership with Henlius to commercialize Henlius for an undisclosed sum. This collaboration enables Organon to obtain the commercialization rights for biosimilar candidates referencing Perjeta (Pertuzumab, HLX11) and Prolia or Xgeva (Denosumab). The agreement aligns with Organon's expertise in biosimilar commercialization and its dedication to providing high-quality and cost-effective biologic medicines globally, with a specific focus on women's health. Henlius, a biopharmaceutical company based in China, specializes in the development of Denosumab biosimilars, including HLX14.

Major companies operating in the denosumab market report are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, Sanofi SA, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Asahi Kasei Corporation, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, Mylan N.V., Sandoz International GmbH, Daiichi Sankyo Company Limited, Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Celltrion Inc., Amneal Pharmaceuticals Inc, Cadila Healthcare Limited, Lupin Limited, Biocon Limited, Torrent Pharmaceuticals Ltd., Jubilant Life Sciences Limited, Ajanta Pharma Limited.

North America was the largest region in the denosumab market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the denosumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The denosumab market consists of sales of calcium supplements and vitamin D supplements. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Denosumab is a monoclonal antibody employed in the treatment of bone-related conditions, particularly osteoporosis and bone metastases. Its mechanism of action involves inhibiting osteoclast formation, reducing bone resorption, increasing bone mineral density, and consequently lowering the risk of fractures.

The main classifications of denosumab drugs include Prolia, Xgeva, and others. Prolia is a prescription medicine specifically used for treating osteoporosis in postmenopausal women who are at a high risk of fractures or cannot use another osteoporosis medication. This drug is available in 60 mg and 120 mg doses and is utilized by various end-users such as hospitals, home care services, specialty clinics, and ambulatory surgical centers.

The denosumab market research report is one of a series of new reports that provides denosumab market statistics, including denosumab industry global market size, regional shares, competitors with a denosumab market share, detailed denosumab market segments, market trends and opportunities, and any further data you may need to thrive in the denosumab industry. This denosumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.